Published online Mar 24, 2016. doi: 10.5500/wjt.v6.i1.144
Peer-review started: August 7, 2015
First decision: October 16, 2015
Revised: November 16, 2015
Accepted: December 29, 2015
Article in press: January 4, 2016
Published online: March 24, 2016
Core tip: Tacrolimus is an immunosuppressive agent to prevent and treat allograft rejection in solid organ transplant recipients. An extended release tacrolimus formulation known as Astagraf XL is now available which allows for once-daily dosing, with the potential to improve adherence. Both tacrolimus formulations have demonstrated comparable steady-state systemic tacrolimus exposure in de novo kidney and liver transplant recipients. The following review will address the pharmacokinetics of extended release tacrolimus, the data in solid-organ transplantation and the phamacoeconomic considerations of extended release tacrolimus compared to twice daily tacrolimus.